Drug Trial Radar · NCT06822790
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
710
Actual
Start
Apr 9, 2025
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133). Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of \<=10% within 30 days prior to Day 1. Subjects entering this OLE from AROAPOC3-2003 must meet the following additional criteria to be considered for enrollment in addition to applicable eligibility criteria: 1. HbA1c ≤10% within 30 days prior to Day 1 2. Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND fulfill either (c) or (d) 3. Baseline fasting TG level of ≥500 mg/dL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001 4. Baseline fasting TG level of ≥1000 mg/dL at the time of enrollment into AROAPOC3-2001 All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet throughout the study in accordance with local standard of care.
Conditions
- Hypertriglyceridemia
Interventions
Plozasiran InjectionDrug
ARO-APOC3 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through Month 24
Locations
253 sites in 24 countries. Site status is shown where the registry gives one.
Research Site 21
Bakersfield, California
Research Site 9
Beverly Hills, California
Research Site 11
Canoga Park, California
Research Site 40
Garden Grove, California
Research Site 235
Huntington Beach, California
Research Site 236
Lake Forest, California
Research Site 39
Lincoln, California
Research Site 34
Oxnard, California
Research Site 229
Palm Springs, California
Research Site 275
Redding, California
Research Site 14
Hialeah, Florida
Research Site 154
Miami, Florida
Research Site 1
Miami Lakes, Florida
Research Site 42
Mt. Dora, Florida
Research Site 41
Orlando, Florida
Research Site 16
Tamarac, Florida
Research Site 18
Tampa, Florida
Research Site 237
Lawrenceville, Georgia
Research Site 17
Park Ridge, Illinois
Research Site 43
Elkhart, Indiana
Research Site 157
Indianapolis, Indiana
Research Site 28
Overland Park, Kansas
Research Site 23
Topeka, Kansas
Research Site 12
Annapolis, Maryland
Research Site 44
Baltimore, Maryland
Research Site 30
Flint, Michigan
Research Site 290
Minneapolis, Minnesota
Research Site 33
Jackson, Mississippi
Research Site 32
Olive Branch, Mississippi
Research Site 2
Jefferson City, Missouri
Research Site 232
St Louis, Missouri
Research Site 29
Fremont, Nebraska
Research Site 3
Omaha, Nebraska
Research Site 77
Summit, New Jersey
Research Site 72
Long Island City, New York
Research Site 233
New York, New York
Research Site 228
New York, New York
Research Site 273
Riverhead, New York
Research Site 37
Asheboro, North Carolina
Research Site 36
Morehead City, North Carolina
Showing 40 of 253 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.